Mitochondrial pyruvate carrier inhibition initiates metabolic crosstalk to stimulate branched chain amino acid catabolism
Objective: The mitochondrial pyruvate carrier (MPC) has emerged as a therapeutic target for treating insulin resistance, type 2 diabetes, and nonalcoholic steatohepatitis (NASH). We evaluated whether MPC inhibitors (MPCi) might correct impairments in branched chain amino acid (BCAA) catabolism, whic...
Main Authors: | Daniel Ferguson, Sophie J. Eichler, Nicole K.H. Yiew, Jerry R. Colca, Kevin Cho, Gary J. Patti, Trevor M. Shew, Andrew J. Lutkewitte, Sandip Mukherjee, Kyle S. McCommis, Natalie M. Niemi, Brian N. Finck |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2023-04-01
|
Series: | Molecular Metabolism |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2212877823000285 |
Similar Items
-
The Hepatic Mitochondrial Pyruvate Carrier as a Regulator of Systemic Metabolism and a Therapeutic Target for Treating Metabolic Disease
by: Kyle S. McCommis, et al.
Published: (2023-01-01) -
Identification of Novel Mitochondrial Pyruvate Carrier Inhibitors by Homology Modeling and Pharmacophore-Based Virtual Screening
by: Lamees Hegazy, et al.
Published: (2022-02-01) -
Phosphonate Inhibitors of Pyruvate Dehydrogenase Perturb Homeostasis of Amino Acids and Protein Succinylation in the Brain
by: Artem V. Artiukhov, et al.
Published: (2022-10-01) -
Mitochondrial Pyruvate Carrier Function in Health and Disease across the Lifespan
by: Jane L. Buchanan, et al.
Published: (2020-08-01) -
Psychometric validation of the Pyruvate Kinase Deficiency Diary and Pyruvate Kinase Deficiency Impact Assessment in adults in the phase 3 ACTIVATE trial
by: David A. Andrae, et al.
Published: (2023-11-01)